Inclusion Criteria	Exclusion Criteria
• **≥ 3 years of age** • Diagnosis of Pompe disease* • **Naïve to treatment with alglucosidase alfa** or any investigational therapy for Pompe disease • Able to successfully perform repeated **FVC measurements of >30% & <85% predicted** (upright) • **Able to ambulate 40 meters** (≈130 feet) without stopping and without an ambulation assistance device	• Pompe-specific cardiac hypertrophy • **Requires invasive ventilation** (non-invasive ventilation is allowed) • **Wheelchair dependency** • Clinically significant organic disease, apart from Pompe disease-related symptoms • Prior or current use of immune tolerance induction therapy • Pregnant or breastfeeding • Female patient of childbearing potential not protected by highly effective contraceptive method of birth control and/or is unwilling or unable to be tested for pregnancy

*Confirmed by GAA enzyme deficiency from any tissue source and/or 2 confirmed *GAA* gene variants.

FIG. 1



Enrollment
n=100
R+
1:1
20 mg/kg alglucosidase alfa IV qow
(25 doses, n=49)
20 mg/kg avalglucosidase alfa IV qow
(25 doses, n=51)
20 mg/kg avalglucosidase alfa IV qow
(120 doses)
Post-treatment
Follow-up
Screening* and
randomization+
Baseline
Primary Analysis Period (PAP)*
49 weeks
Extended Treatment Period (ETP)§
Up to 238 weeks
Post-treatment
follow-up
Up to 4 weeks

FIG. 2



Patients Screened
N=146
Screen Failures
N=46
Patients Randomized
N=100
Alglucosidase alfa
N=49
Avalglucosidase alfa
N=51
Discontinued (N=5)
• Adverse Event: n=4
• Other: n=1
Completed PAP
N=44
Completed PAP
N=51
Entered ETP
N=95
Discontinued (N=4)
• Adverse Event: n=3
• Other: n=1
Ongoing in ETP
N=91

FIG. 3

Parameter	Avalglucosidase alfa N=51	Alglucosidase alfa N=49	Total N=100
Age (years)			
Mean (SD)	46.0(14.5)	50.3(13.7)	48.1(14.2)
Median (Min, Max)	47.7 (16, 78)	48.9 (20, 78)	48.5 (16, 78)
Gender, n (%)			
Male	27 (52.9)	25 (51.0)	52 (52.0)
Females	24 (47.1)	24 (49.0)	48 (48.0)
Race, n (%)			
Asian	3 (5.9)	0	3 (3.0)
Black/African American	1 (2.0)	2 (4.1)	3 (3.0)
White	47 (92.2)	47 (95.9)	94 (94.0)
Ethnicity, n (%)			
Hispanic or Latino	3 (5.9)	12 (24.5)	15 (15.0)
Not Hispanic or Latino	44 (86.3)	32 (65.3)	76 (76.0)
Not Reported	4 (7.8)	5 (10.2)	9 (9.0)
Regions, n (%)			
Europe	31 (60.8)	21 (42.9)	52 (52.0)
North America	14 (27.5)	20 (40.8)	34 (34.0)
Latin America	2 (3.9)	7 (14.3)	9 (9.0)
Asia-Pacific	4 (7.8)	1 (2.0)	5 (5.0)

FIG. 4

Parameter	Avalglucosidase alfa N=51	Alglucosidase alfa N=49	Total N=100
FVC% Predicted, Upright			
Mean (SD)	62.5(14.4)	61.6(12.4)	62.1(13.4)
Median (Min, Max)	65.5 (32, 85)	60.8 (39, 85)	63.2 (32, 85)
6MWT (Distance Walked), m			
Mean (SD)	399.3(110.9)	378.1(116.2)	388.9(113.5)
Median (Min, Max)	415.7(118, 630)	387.0 (138, 592)	403.5 (118, 630)
6MWT % Predicted			
Mean (SD)	57.3(15.0)	55.3 (16.6)	56.3(15.8)
Median (Min, Max)	61.0(19, 86)	56.6(23,102)	59.1(19,102)
MIP % Predicted, Upright*			
Mean (SD)	59.9(47.1)	60.6 (41.0)	60.3 (44.0)
Median (Min, Max)	47.6 (9, 263)	51.1(18,234)	48.1(9,263)
MEP % Predicted, Upright*			
Mean (SD)	65.77(38.97)	74.83 (35.22)	70.25 (37.25)
Median (Min, Max)	54.21 (28.7,232.5)	68.00(19.7, 201.1)	59.56 (19.7, 232.5)

FIG. 5

Parameter	Avalglucosidase alfa N=51	Alglucosidase alfa N=49	Total N=100
HHD (lower extremity), composite	n=50	n=46	n=96
Mean (SD)	1330.45 (625.44)	1466.16 (604.91)	1395.48 (616.23)
Median (Min, Max)	1193.50 (323.0,3522.0)	1427.50(329.0,3218.0)	1290.00 (323.0,3522.0)
QMFT	n=51	n=46	n=97
Mean (SD)	41.29(10.15)	42.30(10.58)	41.77(10.32)
Median (Min, Max)	41.00 (17.0, 63.0)	43.50 (19.0, 63.0)	41.00(17.0, 63.0)
SF-12 (PCS)	n=50	n=48	n=98
Mean (SD)	35.95 (7.82)	36.76 (9.40)	36.35 (8.60)
Median (Min, Max)	35.01 (17.8,55.9)	36.04(16.3,57.3)	35.40(16.3,57.3)
SF-12 (MCS)	n=50	n=48	n=98
Mean (SD)	48.31 (10.11)	50.58 (8.69)	49.42 (9.46)
Median (Min, Max)	47.53 (24.2,70.8)	52.24 (30.4, 65.0)	50.21 (24.2, 70.8)

FIG. 6

	Avalglucosidase alfa N=51	Alglucosidase alfa N=49
Mean (SD) duration of study drug exposure, months	11.56(0.14)	10.69 (2.69)
Mean number (SD) of infusions	24.8(0.5)	22.8(5.8)
Mean patient year	0.96	0.91

FIG. 7



FVC % Predicted
LS Mean Absolute Change from Baseline to Week 49
LS Mean (SE) Change from Baseline (%)
4
3.5
3
2.5
2
1.5
1
0.5
0
+2.43
p=0.0074
(margin=1.1%)
2.89%
p=0.0626
0.46%
Avalglucosidase alfa
Alglucosidase alfa

FIG. 8A



6MWT Distance (m)
LS Mean Absolute Change from Baseline to Week 49
LS mean (SE) Change from Baseline (m)
40
35
30
25
20
15
10
5
0
+30.01
p=0.0405
32.21
2.19
Avalglucosidase alfa
Alglucosidase alfa

FIG. 8B



FVC % Predicted
LS Mean Change (95% CI) from Baseline to Week 49
-0.13
2.43
4.99
-Δ: -1.1
-4
-2
0
2
4
Favors alglucosidase alfa
Favors avalglucosidase alfa
(margin=-1.1%): p=0.0074
p=0.0626

FIG. 9A



6MWT Distance (m)
LS Mean Change (95% CI) from Baseline to Week 49
1.33
30.01
58.69
-60
-40
-20
0
20
40
60
Favors alglucosidase alfa
Favors avalglucosidase alfa
p=0.0405

FIG. 9B



LS Mean Change in FVC % Predicted
Baseline to Week 49
LS Mean (SE) Change FVC % Predicted
4
3
2
1
0
-1
+2.89%
+0.46%
Avalglucosidase alfa
Alglucosidase alfa
Baseline
Week 13
Week 25
Week 37
Week 49

FIG. 10



LS Mean Change in 6MWT Distance (m)
Baseline to Week 49
LS Mean (SE) Change in 6MWT Distance (m)
40
30
20
10
0
-10
+32.21
+2.19
Avalglucosidase alfa
Alglucosidase alfa
Baseline
Week 13
Week 25
Week 37
Week 49

FIG. 11



LS Mean Change in 6MWT Distance % Predicted
Baseline to Week 49
LSI Mean (SE) Change in 6MWT Distance % Predicted
7
6
5
4
3
2
1
0
-1
-2
+5.02%
+0.31%
Avalglucosidase alfa
Alglucosidase alfa
Baseline
Week 13
Week 25
Week 37
Week 49

FIG. 12




FIG. 13A

Difference (LS Mean [SE]): 2.58 (5.59); p=0.6451
95% CI: -8.54, 13.7




FIG. 13B

Difference (LS Mean [SE]): -2.61 (5.83); p=0.6557
95% CI: -14.11, 9



HHD Composite Score
LS Mean Change: Baseline to Week 49
LS Mean Change (SE) in HHD Composite Score (Newton)
300
250
200
150
100
50
0
Avalglucosidase alfa
Alglucosidase alfa
260.69
(46.07)
153.72
(48.54)
Baseline
Week 13
Week 25
Week 37
Week 49

FIG. 14



LS Mean Change in QMFT Total Score
Baseline to Week 49
LS Mean Change (SE) in QMFT Total Score
5
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
3.98
(0.63)
1.89
(0.69)
Avalglucosidase alfa
Alglucosidase alfa
Baseline
Week 13
Week 25
Week 37
Week 49

FIG. 15




FIG. 16A

Difference (LS Mean [SE]): 0.77 (1.46); p=0.5996
95% CI: -2.13, 3.67




FIG. 16B

Difference (LS Mean [SE]): 2.12 (1.80); p=0.2427
95% CI: -1.46, 5.69

	Avalglucosidase alfa N=51	Alglucosidase alfa N=49
TEAEs	44 (86.3)	45 (91.8)
TEAEs Potentially Related to Treatment	23 (45.0)	24 (49.0)
Serious TEAEs	8 (15.7)	12 (24.5)
Serious TEAEs Potentially Related to Treatment	**1 (2.0)**	**3(6.1)**
Severe TEAEs	6 (11.8)	7 (14.3)
TEAEs Leading to Study Withdrawal	0	4(8.2)
TEAEs Leading to Death	0	1 (2.0)
IARs (protocol-defined)*	**13 (25.5)**	**16 (32.7)**

FIG. 17




FIG. 18A

95% CI: -1.95, 2.25; p=0.8854




FIG. 18B

95% CI: -3.87, 50.51; p=0.0918

Parameter, n (%)	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Total (N=100)
Number of randomized but not treated patients[a]	0	0	0
Number of randomized and treated patients[a]	51 (100)	49 (100)	100 (100)
Treatment in PAP prematurely discontinued	0	5 (10.2)	5(5.0)
Reason for PAP premature discontinuation			
Adverse Event	0	4(8.2)	4 (4.0)
Other	0	1 (2.0)	1 (1.0)
Treatment in PAP completed	51 (100)	44 (89.8)	95 (95.0)
Did not enter into ETP	0	0	0
Entered into ETP	51 (100)	44 (89.8)	95 (95.0)
Treatment in ETP ongoing	48(94.1)	43 (87.8)	91 (91.0)
Treatment in ETP completed	0	0	0
Treatment in ETP prematurely discontinued	3(5.9)	1 (2.0)	4 (4.0)
Reason for ETP premature discontinuation			
Adverse Event	2(3.9)	1 (2.0)	3(3.0)
Other	1 (2.0)	0	1 (1.0)
Efficacy populations			
mITT[b]	51 (100)	49 (100)	100 (100)
Per Protocol	46(90.2)	39 (79.6)	85 (85.0)
Safety population[c]	51 (100)	49 (100)	100 (100)
Number of randomized and treated patients at Week 97	24(47.1)	22 (44.9)	46 (46.0)

Percentages are calculated using the number of randomized patients as the denominator

a. For any subject randomized more than once, only the data associated with the first randomization will be used in any analysis population.

b. MITT population includes randomized patients who receive at least 1 infusion (partial or total).

c. Safety population includes patients who received at least 1 infusion (partial or total).

d. Per Protocol population includes mITT population with no major protocol deviation expected to interfere with assessments of the primary endpoint.

FIG. 19

Parameter	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Total (N=100)
Age (years)	Number	51	49	100
	Mean (SD)	46.0(14.5)	50.3(13.7)	48.1 (14.2)
	Median	47.7	48.9	48.5
	Min; Max	16; 78	20; 78	16; 78
Age (years) - categorized	Number	5l	49	100
	<18	1 (2.0)	0	1 (1.0)
	≥18 and <45	23 (45.1)	19(38.8)	42 (42.0)
	≥45	27 (52 9)	30(61.2)	57(57.0)
Gender, n(%)	Number	51	49	100
	Male	27 (52.9)	25(51.0)	52 (52.0)
	Female	24 (47.1)	24 (49.0)	48 (48.0)
Race, n(%)	Number	51	49	100
	American Indian or Alaska Native	0	0	0
	Asian	3(5.9)	0	3(3.0)
	Black or African American	1 (2.0)	2(4.1)	3(3.0)
	Native Hawaiian or Other Pacific Islander	0	0	0
	White	47 (92.2)	47 (95.9)	94 (94.0)
	Not Reported	0	0	0
Ethnicity, n(%)	Number	51	49	100
	Hispanic or Latino	3(5.9)	12(24.5)	15(15.0)
	Not Hispanic or Latino	44 (86.3)	32 (65.3)	76 (76.0)
	Unknown	0	0	0
	Not reported	4(7.8)	5(10.2)	9 (9.0)
Regions, n(%)	Number	51	49	100
	Europe	31(60.8)	21 (42.9)	52 (52.0)
	North America	14 (27.5)	20(40.8)	34 (34.0)
	Latin America	2(3.9)	7(14.3)	9 (9.0)
	Asia-Pacific	4(7.8)	1(2.0)	5(5.0)
Weight (kg)	Number	51	49	100
	Mean (SD)	77.8(22.1)	79.3(18.2)	78 5 (20.2)
	Median	75.9	78.6	76.4
	Min; Max	38; 129	46; 139	38; 139
Height (cm)	Number	51	49	100
	Mean (SD)	170.9(9.7)	172.0(8.9)	171.5 (9.3)
	Median	169.8	171.5	170.3

FIG. 20A

Parameter	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Total (N=100)
	Min; Max	145;193	158; 191	145; 193
BMI (kg/m2)	Number	51	49	100
	Mean (SD)	26.39 (6.79)	26.69(5.42)	26.54 (6.13)
	Median	25.40	27.40	26.45
	Min; Max	14.0; 42.7	16.9; 44.6	14.0; 44.6
Alcohol Habit n(%)	Number	51	49	100
	Never	21 (41.2)	17(34.7)	38 (38.0)
	Occasional	18 (35.3)	20 (40.8)	38 (38.0)
	At least monthly	4(7.8)	3(6.1)	7(7.0)
	At least weekly	5(9.8)	5(10.2)	10 (10.0)
	At least daily	3(5.9)	4(8.2)	7(7.0)
Randomization Strata, n(%)	Number	51	49	100
	Age<18	1 (2.0)	0	1 (1.0)
	Age≥18, Japan	1 (2.0)	0	1 (1.0)
	Age≥18, male and FVC<55%, ex-Japan	10 (19.6)	11(22.4)	21 (21.0)
	Age≥18, female and FVC<55%, ex-Japan	5(9.8)	5(10.2)	10 (10.0)
	Age≥18, male and FVC≥55%, ex-Japan	15 (29.4)	14(28.6)	29(29.0)
	Age≥18, female and FVC≥55%, ex-Japan	19 (37.3)	19 (38.8)	38 (38.0)

FIG. 20B

Parameter	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Total (N=100)
Cardiovascular History				
Congestive Heart Failure [n(%)]	Number	51	49	100
	Yes	1(2.0)	2(4.1)	3(3.0)
	No	50 (98.0)	47(95.9)	97(97.0)
NYHA Heart Failure Classification [n(%)]	Number	51	49	100
	Class I	0	2(4.1)	2(2.0)
	Class II	1(2.0)	0	1 (1.0)
	Class III	0	0	0
	Class IV	0	0	0
	No	50 (98.0)	47(95.9)	97(97.0)
Evidence of Cardiac Involvement [n(%)]	Number	51	49	100
	Yes	0	4(8.2)	4(4.0)
	No	51 (100)	45 (91.8)	96 (96.0)

FIG. 21A

Parameter	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Total (N=100)
Specify Cardiac Involvement [n(%)]	Number	0	3	3
	Arrhythmia	0	2(66.7)	2(66.7)
	Cardiomegaly	0	0	0
	Other	0	1 (33.3)	1 (33.3)
Ear/Nose/Throat History Enlarged Tongue [n(%)]	Number	51	49	100
	Yes	2(3.9)	4(8.2)	6 (6.0)
	No	49(96.1)	45 (91.8)	94(94.0)
Hearing Loss [n(%>]	Number	51	48	99
	Yes	6(11.8)	4(8.3)	10(10.1)
	No	45 (88.2)	44(91.7)	89 (89.9)
Gastrointestinal History Hepatomegaly [n(%)]	Number	51	49	100
	Yes	0	2(4.1)	2 (2.0)
	No	51 (100)	47 (95.9)	98 (98.0)
Gastroesophageal Reflux [n(%)]	Number	51	49	100
	Yes	6(11.8)	6(12.2)	12(12.0)
	No	45 (88.2)	43 (87.8)	88 (88.0)
Respiratory History Tracheostomy [n(%)]	Number	51	49	100
	Yes	1(2.0)	0	1 (1.0)
	No	50 (98.0)	49 (100)	99 (99.0)
Pneumonia [n(%)]	Number	51	49	100
	Yes	10(19.6)	9 (18.4)	19(19.0)
	No	41 (80.4)	40(81.6)	81 (81.0)
Number of pneumonia episodes in the past year [n(%)]	Number	10	9	19
	<5	10(100)	9 (100)	19(100)
	5-10	0	0	0
	>10	0	0	0
Sleep Disturbances [n(%)]	Number	51	49	100
	Yes	12(23.5)	18 (36.7)	30(30.0)
	No	39 (76.5)	31 (63.3)	70(70.0)
If Sleep Disturbance, Sleep Study Ever Performed?	Number	12	18	30
	Yes	9 (75.0)	10(55.6)	19(63.3)
	No	3(25.0)	8 (44.4)	11(36.7)
Sleep Apnea [n(%)]	Number	51	49	100
	Yes	10(19.6)	13 (26.5)	23 (23.0)
	No	41 (80.4)	36 (73.5)	77 (77.0)
Use of Non-invasive Respiratory Support [n(%)]	Number	51	49	100
	Yes	13(25.5)	11(22.4)	24(24.0)
	No	38 (74.5)	38 (77.6)	76(76.0)

FIG. 21B

Parameter	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Total (N=100)
Musculoskeletal History				
Muscle Weakness in Upper Extremities [n(%)]	Number	51	49	100
	Yes	31 (60.8)	24 (49.0)	55 (55.0)
	No	20 (39.2)	25(51.0)	45 (45.0)
Muscle Weakness in Lower Extremities [n(%)]	Number	51	49	100
	Yes	48(94.1)	42 (85.7)	90 (90.0)
	No	3 (5.9)	7(14.3)	10(10.0)
Scoliosis [n(%)]	Number	50	49	99
	Yes	13 (26.0)	9 (18.4)	22 (22.2)
	No	37 (74.0)	40(81.6)	77 (77.8)
Surgical Intervention for Scoliosis [n(%)]	Number	17	15	32
	Yes	0	0	0
	No	17(100)	15(100)	32 (100)
Currently Using Orthopedic Devices for Scoliosis [n(%)]	Number	17	13	30
	Yes	0	1(7-7)	1 (3.3)
	No	17(100)	12 (92.3)	29 (96.7)
Joint Contractures [n(%)]	Number	51	49	100
	Yes	0	2(4.1)	2(2.0)
	No	51(100)	47 (95.9)	98 (98.0)
Surgical Repair Needed for Joint Contractures [n(%)]	Number	4	7	11
	Yes	0	0	0
	No	4 (100)	7(100)	11(100)
Currently Using Orthopedic Devices for Joint Contractures [n(%)]	Number	4	8	12
	Yes	0	0	0
	No	4 (100)	8 (100)	12(100)
Currently Ambulatory [n(%)]	Number	50	49	99
	Yes	48 (96.0)	48 (98.0)	96 (97.0)
	No	2(4.0)	1 (2.0)	3(3.0)
	Ever ambulatory?	0	0	0
Assisted Walking Device and Wheelchair Use [n(%)]	Number	51	49	100
	None	41 (80.4)	38 (77.6)	79 (79.0)
	Cane	7(13.7)	9 (18.4)	16(16.0)
	Walker	2(3.9)	3(6.1)	5(5.0)
	Wheelchair	0	1 (2.0)	1 (10)
	Other	4(7.8)	4(8.2)	8 (8.0)
Pompe disease history				
Age at Pompe Disease Diagnosis (years)	Number	51	49	100

FIG. 21C

Parameter	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Total (N=100)
	Mean (SD)	44.73 (14.74)	48.16 (14.64)	46.41 (14.72)
	Median	47.05	47.34	47.14
	Min; Max	10.8; 77.7	17.1; 76.7	10.8; 77.7
Age at First Symptom of Pompe Disease (years)	Number	50	49	99
	Mean (SD)	32.94 (16.58)	37.73 (15.74)	35.31 (16.27)
	Median	32.35	39.42	38.89
	Min; Max	3.8;66.3	6.1; 73.2	3.8; 73.2
Time from Pompe Disease Diagnosis to First Infusion of Study Drug (months)	Number	51	49	100
	Mean (SD)	15.60 (32.06)	26.52 (59.86)	20.95 (47.82)
	Median	6.08	7.85	6.92
	Min; Max	0.5; 155.2	0.3; 328.4	0.3; 328.4
Time from First Symptom of Pompe Disease to First Infusion of Study Drug (months)	Number	50	49	99
	Mean (SD)	160.36 (131.71)	151.78 (120.90)	156.11 (125.91)
	Median	137.91	124.91	128.92
	Min; Max	10.5; 698.9	5.0; 458.4	5.0;698.9
Family History of Pompe Disease [n(%)]	Number	51	49	100
	Yes	13 (25.5)	15 (30.6)	28 (28.0)
	No	38 (74.5)	34(69.4)	72(72.0)
Relationship to Subject [n(%)]	Number	13	15	28
	Sibling	12 (92.3)	15 (100)	27(96.4)
	Mother	0	0	0
	Father	0	0	0
	Cousin	1(7.7)	0	1(3.6)
	Children	0	0	0

FIG. 21D

Parameter	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Total (N=100)
Predicted FVC (%), upright	Number	51	49	100
	Mean (SD)	62.5 (14.4)	61.6(12.4)	62.1 (13.4)
	Median	65.5	60.8	63.2
	Min; Max	32; 85	39; 85	32; 85
Distance Walked from 6MWT (m)	Number	51	49	100
	Mean (SD)	399.3 (110.9)	378.1 (116.2)	388.9 (113.5)
	Median	415.7	387.0	403.5
	Min; Max	118; 630	138; 592	118; 630
6MWT (% predicted)	Number	51	49	100

FIG. 22A

Parameter	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Total (N=100)
	Mean (SD)	57.3 (15.0)	55.3 (16.6)	56.3 (15.8)
	Median	61.0	56.6	59.1
	Min; Max	19;86	23; 102	19; 102
% Predicted MIP (%)[a], upright	Number	50	49	99
	Mean (SD)	59.9(47.1)	60.6(41.0)	60.3 (44.0)
	Median	47.6	51.1	48.1
	Min; Max	9; 263	18;234	9; 263
% Predicted MEP (%)[a], upright	Number	50	49	99
	Mean (SD)	65.77(38.97)	74.83 (35.22)	70.25 (37.25)
	Median	54.21	68.00	59.56
	Min; Max	28.7; 232.5	19.7; 201.1	19.7; 232.5
HHD (Lower extremity) composite score	Number	50	46	96
	Mean (SD)	1330.45 (625.44)	1466.16 (604.91)	1395.48 (616.23)
	Median	1193.50	1427.50	1290.00
	Min; Max	323.0; 3522.0	329.0; 3218.0	323.0; 3522.0
% Predicted HHD (Lower extremity) composite score	Number	50	46	96
	Mean (SD)	40.05 (21.76)	45.02 (23.27)	42.43 (22.52)
	Median	30.51	40.60	38.61
	Min; Max	7.1; 112.7	9.6; 119.4	7.1; 119.4
HHD (upper extremity) composite score	Number	46	47	93
	Mean (SD)	1535.95 (673.60)	1608.56(633.95)	1572.65 (651.32)
	Median	1380.00	1501.00	1439.00
	Min; Max	350.5; 3869.0	347.0; 3102.0	347.0; 3869.0
% Predicted HHD (upper extremity) composite score	Number	46	47	93
	Mean (SD)	131.57(59.26)	142.08 (65.59)	136.88 (62.42)
	Median	104.92	131.10	123.00
	Min; Max	42.1 ; 269.8	34.7; 265.6	34.7; 269.8
QMFT	Number	51	46	97
	Mean (SD)	41.29(10.15)	42.30(10.58)	41.77(10.32)
	Median	41.00	43.50	41.00
	Min; Max	17.0; 63.0	19.0; 63.0	17.0; 63.0
SF-12 (PCS)	Number	50	48	98
	Mean (SD)	35.95 (7.82)	36.76(9.40)	36.35 (8.60)
	Median	35.01	36.04	35.40
	Min; Max	17.8; 55.9	16.3; 57.3	16.3; 57.3
SF-12 (MCS)	Number	50	48	98
	Mean (SD)	48.31(10.11)	50.58 (8 69)	49.42 (9.46)
	Median	47.53	52.24	50.21

FIG. 22B

Parameter	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Total (N=100)
	Min; Max	24.2; 70.8	30.4; 65.0	24.2; 70.8
GMFCS [n(%)]	Number	51	49	100
	Level I	10(19.6)	14 (28.6)	24 (24.0)
	Level II	36 (70.6)	27(55.1)	63 (63.0)
	Level III	5(9.8)	8(16.3)	13 (13.0)
	Level IV	0	0	0
	Level V	0	0	0
Walking Device on 6MWT [n(%)]	Number	51	49	100
	Straight cane	4(7.8)	3 (6 .1)	7(7.0)
	Wide-based cane	1(2.0)	1(2.0)	2(2.0)
	One crutch	0	2(4.1)	2(2.0)
	Two crutches	0	0	0
	Standard walker	0	0	0
	Rolling walker	0	3 (6.1)	3(3.0)
	Orthotics	0	0	0
	Other	2(3.9)	1(2.0)	3(3.0)
	None	44 (86.3)	39 (79.6)	83 (83.0)

Note baseline value is defined as the last non-missing value prior to first treatment.
a Because the reference values will be available only for patients of age 7 years or older, the % predicted MIP and MEP will not be derived for patients aged <7.

FIG. 22C

Parameter	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)
Duration of Study Drug Exposure (months)	Number	51	49
	Mean (SD)	11.56 (0.14)	10.69 (2.69)
	Median	11.53	11.50
	Min;Max	11.4;12.4	0.5;11.8
Duration of Study Drug Exposure, n (%)	Number	51	49
	<=3 months	0	3 (6.1)
	<3-<=6 months	0	1 (2.0)
	<6-<=9 months	0	1 (2.0)
	<9-<=12 months	50 (98.0)	44 (89.8)
	>12 months	1 (2.0)	0
Total Number of Infusions Per Patient	Number	51	49
	Mean (SD)	24.8 (0.5)	22.8 (5.8)
	Median	25.0	25.0
	Min; Max	23;25	1;25

FIG. 23A

Parameter	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)
Patient Year	Number	51	49
	Mean (SD)	0.96 (0.01)	0.91 (0.19)
	Median	0.96	0.96
	Min;Max	1.0;1.0	0.0;1.0

Duration of exposure: for those entered in ETP: 1st infusion date in ETP - 1st infusion date in PAP;
For those who did not enter in ETP: last infusion date in PAP + 14 - 1st infusion date in PAP.
Avalglucosidase alfa group includes Patients who were in mITT population and received at least one infusion of avalglucosidase alfa during PAP.
Alglucosidase alfa group includes Patients who were in mITT population and only received alglucosidase alfa during PAP.
Patient year is calculated from the first infusion date to the date of last follow-up visit.

FIG. 23B

	Statistics[a]	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Difference
Week 13	Estimate	3.05	0.65	2.40
	SE	0.78	0.81	1.13
	95% CI	1.50,4.59	-0.95,2.26	0.16,4.63
	p-value for non-inferiority[b]			0.0026
	p-value for superiority			0.0363
Week 25	Estimate	3.21	0.57	2.64
	SE	0.80	0.84	1.17
	95% CI	1.62,4.80	-1.10,2.24	0.32,4.96
	p-value for non-inferiority[b]			0.0018
	p-value for superiority			0.0259
Week 37	Estimate	2.21	0.55	1.66
	SE	1.00	1.05	1.45
	95% CI	0.23,4.19	-1.53,2.64	-1.22,4.54
	p-value for non-inferiority[b]			0.0603
	p-value for superiority			0.2556
Week 49	Estimate	2.89	0.46	2.43
	SE	0.88	0.93	1.29
	95% CI	1.13,4.65	-1.39,2.31	-0.13,4.99
	p-value for non-inferiority[b]			0.0074
	p-value for superiority			0.0626

a. Based on MMRM model, the model includes baseline FVC (% predicted, as continuous), sex, age (in years at baseline), treatment group, visit, interaction term between treatment group and visit as fixed effects.
b. Non-inferiority margin is -1.1%

FIG. 24

Statistics	Difference Between Week 97 and Week 49
Number of subjects with value at Week 49 and Week 97	20
Estimate	0.15
SE	1.06
95% CI	-1.95,2.25
p-value	0.8854

The analysis will be based on % predicted FVC data from Week 49 and subsequent visits in ETP and the MMRM includes visit as a fixed effect and subject as a random effect.

FIG. 25

Analysis Visit	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Difference
Week 13				
6MWT total distance change from baseline	Estimate	18.02	15.11	2.91
	SE	8.79	9.16	12.75
	95% CI	0.57,35.47	-3.09,33.30	-22.41,28.24
	p-value for superiority			0.8198
6MWT % predicted change from baseline	Estimate	2.84	1.96	0.88
	SE	1.35	1.41	1.96
	95% CI	0.16,5.52	-0.84,4.76	-3.02,4.77
	p-value for superiority			0.6559
Week 25				
6MWT total distance change from baseline	Estimate	27.26	9.58	17.67
	SE	9.98	10.41	14.48
	95% CI	7.43,47.09	-11.10,30.27	-11.08,46.42
	p-value for superiority			0.2253
6MWT % predicted change from baseline	Estimate	4.23	1.13	3.09
	SE	1.54	1.61	2.23
	95% CI	1.17,7.28	-2.06,4.32	-1.34,7.53
	p-value for superiority			0.1697
Week 37				
6MWT total distance change from baseline	Estimate	28.43	15.49	12.94
	SE	9.06	9.48	13.17
	95% CI	10.44,46.42	-3.34,34.31	-13.20,39.09
	p-value superiority			0.3282

FIG. 26A

Analysis Visit	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Difference
6MWT % predicted change from baseline	Estimate	4.44	2.14	2.30
	SE	1.40	1.47	2.04
	95% CI	1.66,7.23	-0.77,5.05	-1.74,6.35
	p-value for superiority			0.2612
Week 49				
6MWT total distance change from baseline	Estimate	32.21	2.19	30.01
	SE	9.93	10.40	14.43
	95% CI	12.47,51.94	-18.48,22.86	1.33,58.69
	p-value for superiority			0.0405
6MWT % predicted change from baseline	Estimate	5.02	0.31	4.71
	SE	1.54	1.62	2.24
	95% CI	1.95,8.09	-2.90,3.52	0.25,9.17
	p-value for superiority			0.0386

6MWT: 6-minute walk test, MMRM: mixed model repeated measure.
The MMRM model for 6MWT distance adjusts for 6MWT distance at baseline, baseline % predicted FVC and baseline 6MWT (distance walked in meter), age (in years, at baseline), gender, treatment group, visit, and treatment-by-visit interaction as fixed effects.
The MMRM model for 6MWT % predicted adjusts for 6MWT % predicted at baseline, baseline % predicted FVC and baseline 6MWT (% predicted), age (in years, at baseline), gender, treatment group, visit, and treatment-by-visit interaction as fixed effects.

FIG. 26B

Statistics	Difference Between Week 97 and Week 49
Number of subjects with value at Week 49 and Week 97	21
Estimate	23.32
SE	13.69
95% CI	-3.87,50.51
p-value	0.0918

The analysis will be based on 6MWT data from Week 49 and subsequent visits in ETP and the MMRM includes visit as a fixed effect and subject as a random effect.

FIG. 27

Analysis Visit	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Difference
Week 13				
MIP % predicted, upright change from baseline	Estimate	-1.18	-0.39	-0.78
	SE	3.70	3.84	5.35
	95% CI	-8.55,6.19	-8.03,7.25	-11.43,9.86
	p-value			0.8837
MEP % predicted, upright change from baseline	Estimate	1.19	5.28	-4 09
	SE	3.65	3.78	5.29
	95% CI	-6.07,8.44	-2.23,12.79	-14.60,6.41
	p-value			0.4412
Week 25				
MIP % predicted, upright change from baseline	Estimate	2.29	-3.15	5.44
	SE	3.35	3.52	4.88
	95% CI	-4.37,8.95	-10.16,3.85	-4.26,15.14
	p-value			0.2676
MEP % predicted, upright change from baseline	Estimate	4.03	2.90	1.14
	SE	3.12	3.28	4.56
	95% CI	-2.18,10.24	-3.64,9.43	-7.94,10.22
	p-value			0.8034
Week 37				
MIP % predicted, upright change from baseline	Estimate	-0.85	3.31	2.45
	SE	3.73	3.92	5.43
	95% CI	-8.28,6.57	-11.12,4.50	-8.35,13.25
	p-value			0.6527
MEP % predicted, upright change from baseline	Estimate	4.19	4.02	0.17
	SE	3.79	3.97	5.52
	95% CI	-3.34,11.72	-3.88,11.92	-10.80,11.14
	p-value			0.9758
Week 49				
MIP % predicted, upright change from baseline	Estimate	-0.29	-2.87	2.58
	SE	3.84	4.04	5.59
	95% CI	-7.94,7.36	-10.92,5.17	-8.54,13.71
	p-value			0.6451
MEP % predicted, upright change from baseline	Estimate	2.39	5.00	-2.61
	SE	4.00	4.20	5.83
	95% CI	-5.59,10.36	-3.36,13.36	-14.22,9.00
	p-value			0.6557

MMRM: mixed model repeated measure
The MMRM model for MIP % predicted adjusts for MIP % predicted at baseline, age (in years, at baseline), gender, treatment group, visit, and treatment-by-visit interaction as fixed effects.
The MMRM model for MEP % predicted adjusts for MEP % predicted at baseline, age (in years, at baseline), gender, treatment group, visit, and treatment-by-visit interaction as fixed effects.

FIG. 28

Analysis Visit	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Difference
Week 13				
Composite score change from baseline	Estimate	146.80	87.29	59.51
	SE	38.26	40.18	55.80
	95% CI	70.75,222.86	7.41,167.17	-51.40,170.42
	p-value			0.2891
Summary score, % predicted change from baseline	Estimate	3.88	2.39	1.49
	SE	1.16	1.20	1.68
	95% CI	1.58,6.18	0.01,4.77	-1.84,4.82
	p-value			0.3767
Week 25				
Composite score change from baseline	Estimate	214.54	99.16	115.38
	SE	41.42	43.64	60.43
	95% CI	132.22,296.87	12.44,185.89	-4.71,235.48
	p-value			0.0595
Summary score, % predicted change from baseline	Estimate	5.21	3.13	2.08
	SE	1.26	1.32	1.83
	95% CI	2.70,7.72	0.50,5.75	-1.56,5.73
	p-value			0.2590
Week 37				
Composite score change from baseline	Estimate	229.41	158.83	70.57
	SE	40.53	42.49	59.01
	95% CI	148.84,309.98	74.37,243.29	-46.71,187.86
	p-value			0.2350
Summary score, % predicted change from baseline	Estimate	5.61	4.80	0.81
	SE	1.23	1.29	1.79
	95% CI	3.16,8.07	2.24,7.37	-2.76,4.37
	p-value			0.6536
Week 49				
Composite score change from baseline	Estimate	260.69	153.72	106.97
	SE	46.07	48.54	67.17
	95% CI	169.11,352.27	57.22,250.22	-26.56,240.50
	p-value			0.1150
Summary score, % predicted change from baseline	Estimate	6.97	4.78	2.18
	SE	1.34	1.41	1.96
	95% CI	4.30,9.63	1.98,7.59	-1.71,6.08
	p-value			0.2681

MMRM: mixed model repeated measure; HHD: hand-held dynamometry;
Muscle strengths are collected in Newton.
The MMRM model for HHD lower extremity muscle strength composite score adjusts for summary HHD lower extremity score at baseline, baseline % predicted FVC, age (in years, at baseline), gender, treatment group, visit, and treatment-by-visit interaction as fixed effects.
The MMRM model for HHD summary score % predicted adjusts for summary score % predicted at baseline, baseline % predicted FVC, age (in years, at baseline), gender, treatment group, visit, baseline % predicted HHD score-by-visit interaction, and treatment-by-visit interaction as fixed effects.

FIG. 29

Analysis Visit	Statistics	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)	Difference
Week 13				
QMFT total score change from baseline	Estimate	2.00	1.09	0.90
	SE	0.55	0.59	0.81
	95% CI	0.91,3.09	-0.08, 2.27	-0.70,2.51
	p- value			0.2673
Week 25				
QMFT total score change from baseline	Estimate	3.27	1.95	1.32
	SE	0.55	0.59	0.81
	95% CI	2.18,4.35	0.77,3.12	-0.29,2.92
	p-value			0.1062
Week 37				
QMFT total score change from baseline	Estimate	3.79	1.66	2.13
	SE	0.60	0.65	0.89
	95% CI	2.60,4.99	0.38,2.95	0.37,3.89
	p-value			0.0183
Week 49				
QMFT total score change from baseline	Estimate	3.98	1.89	2.08
	SE	0.63	0.69	0.94
	95% CI	2.72,5.23	0.52,3.26	0.22,3.95
	p-value			0.0288

QMFT: quick motor function test, MMRM: mixed model repeated measure
The MMRM models adjust for total QMFT score at baseline, baseline % predicted FVC, age (in years, at baseline), gender, treatment group, visit, and treatment-by-visit interaction as fixed effects.

FIG. 30

Analysis Visit	Statistics	avalglucosidase alfa (N-50)	alglucosidase alfa (N=49)	Difference
Week 25				
SF-12 PCS score change from baseline	Estimate	1.03	2.25	-1.21
	SE	0.76	0.78	1.09
	95% CI	-0.48,2.54	0.69,3.80	-3.39,0.96
	p- value			0.2700
SF-12 MCS score change from baseline	Estimate	0.99	1.22	-0.22
	SE	1.08	1.11	1.56
	95% CI	-1.15,3.14	-0.99,3.42	-3.32,2.87
	p-value			0.8864

FIG. 31A

Analysis Visit	Statistics	avalglucosidase alfa (N=50)	alglucosidase alfa (N=49)	Difference
Week 25				
SF-12 PCS score change from baseline	Estimate	2.93	2.03	0.90
	SE	0.81	0.85	1.18
	95% CI	1.32,4.54	0.34,3.72	-1.44,3.24
	p- value			0.4479
SF-12 MCS score change from baseline	Estimate	1.98	1.29	0.69
	SE	1.02	1.07	1.48
	95% CI	-0.04,4.00	-0.83,3.41	-2.25,3.63
	p-value			0.6428
Week 37				
SF-12 PCS score change from baseline	Estimate	2.36	284	-0.48
	SE	0.80	085	1.17
	95% CI	0.77,3.95	1.15,4.52	-2.80,1.84
	p-value			0.6816
SF-12 MCS score change from baseline	Estimate	2.72	-0.41	3.13
	SE	1.02	1.08	1.49
	95% CI	0.69,4.74	-2.56,1.73	0.17,6.09
	p- value			0.0388
Week 49				
SF-12 PCS score change from baseline	Estimate	2.37	1.60	0.77
	SE	0.99	1.07	1.46
	95% CI	0.40,4.34	-0.52,3.72	-2.13,3.67
	p-value			0.5996
SF-12 MCS score change from baseline	Estimate	2.88	0.76	2.12
	SE	1.22	1.32	1.80
	95% CI	0.47,5.30	-1.86,3.39	-1.46,5.69
	p- value			0.2427

SF-12:12-item short form health survey, PCS: physical component summary, MCS: mental component summary, MMRM: mixed model repeated measure

The MMRM models adjust for baseline score (PCS or MCS), baseline % predicted FVC, age (in years, at baseline), gender, treatment group, visit, and treatment-by-visit interaction as fixed effects.

FIG. 31B

Parameter, n (%)	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)
TEAEs	45(88.2)	45 (91.8)
TEAEs potentially related to Study Treatment	24 (47.1)	24 (49.0)

FIG. 32A

Parameter, n (%)	avalglucosidase alfa (N=51)	alglucosidase alfa (N=49)
Serious TEAEs	8(15.7)	12 (24.5)
Serious TEAEs potentially related to Study Treatment	1 (20)	3 (6.1)
Severe TEAEs	6(11.8)	7(14.3)
TEAEs leading to permanent treatment discontinuation	0	4(8.2)
TEAEs leading to death	0	1 (2.0)
Protocol-defined IARs	14 (27.5)	16(32.7)
Algorithm-defined IARs	15(29.4)	20 (40.8)

TEAE: treatment-emergent adverse event; IAR: infusion associated reaction
n (%) = number and percentage of patients/subjects with at least one TEAE in each category.
Include adverse events that developed, worsen or became serious on or after the 1st infusion of study drug in PAP and (1) up to 28 days after last infusion in PAP for patients who did not enter ETP
or (2) up to 28 days after last infusion in PAP or date and time just prior to 1st infusion in ETP, whichever occur earlier, for those who entered ETP.
Protocol defined IAR: IARs defined as AESIs that occurred during either infusion or observation period following infusion, related or possibly related to IMP. At the discretion of Investigator, AEs occurring after completion of post infusion observation period assessed as related could also be considered IARs.
Algorithm defined IAR: any IMP-related TEAE that occurred from start of infusion plus 24 hours window or any TEAE meeting the following criterion: if AE start date is non-missing but time component is missing, compare AE Start date with infusion start date (date component only) and infusion end date (date component only). If AE Start date is between infusion start date and infusion end date plus 1 day, consider such AE as Algorithm-defined IAR if AE is related to study drug (missing relatedness is assumed related).
Protocol rules for IARs reporting: In instances where a patient experiences an IAR, allergic, or anaphylactic reaction, either during infusion or post-observation period, each of the individual signs and/or symptoms comprising the reaction were to be captured as individual AE terms.

FIG. 32B




FIG. 33A




FIG. 33B

Parameter	Avalglucosidase alfa N=51	Alglucosidase alfa N=49	Total N=100
Urinary Hex4 (mmol/mol)	n=51	n=49	
Mean (SD)	12.71 (10.10)	8.74 (5.04)	-
Median (Min, Max)	8.55 (3.0, 48.0)	7.30 (2.0, 25.3)	-
ALT (IU/L)	n=50	n=49	
Mean (SD)	81.30(56.51)	60.76 (30.28)	-
Median (Min, Max)	66.50 (24.0, 319.0)	58.0 (12.0, 186.0)	-
AST (IU/L)	n=50	n=49	
Mean (SD)	79.64 (55.58)	57.73 (25.49)	-
Median (Min, Max)	59.0 (27.0, 285.0)	54.0(16.0,141.0)	-
Creatine Kinase (IU/L)	n=50	n=48	
Mean (SD)	739.9 (577.62)	566.35 (431.46)	-
Median (Min, Max)	583.0(158.0, 3128.0)	471.0 (66.0, 2545.0)	-
Creatine Kinase MB (µg/L)	n=49	n=48	
Mean (SD)	15.64(10.49)	16.69 (12.98)	-
Median (Min, Max)	12.9 (2.4, 42.7)	13.65 (1.1, 55.1)	-

FIG. 34




FIG. 35A




FIG. 35B




FIG. 35C




FIG. 35D

	Avalglucosidase alfa N=51	Alglucosidase alfa N=49
ADA Status, n (%)		
Always negative	2(3.9)	2 (4.2)
Ever positive but negative at baseline	47 (92.2)	44 (91.7)
Positive at baseline	2(3.9)	2 (4.2)
Treatment-emergent ADA, n (%[a])	49 (96.1)	46 (95.8)
Treatment-induced ADA, n (%[b])	47 (95.9)	44 (95.7)
Transient ADA	1 (2.0)	1 (2.2)
Persistent ADA	43 (87.8)	39 (84.8)
Tolerized ADA	3(6.1)	4(7.7)
Treatment-boosted ADA, n (%[c])	2 (100)	2(100)
ADA peak titer, n (%)		
100-800	17 (33.3)	8(16.7)
1600-6400	20 (39.2)	20 (41.7)
≥12,800	10(19.6)	16 (33.3)
NAb response type based on enzyme activity inhibition, n (%)		
Always negative	49 (96.1)	44 (91.7)
Positive at baseline	0	0
Positive post baseline	2(3.9)	4(8.3)
NAb response type based on enzyme uptake inhibition, n (%)		
Always negative	38 (74.5)	28 (58.3)
Positive at baseline	1(2.0)	1(2.1)
Positive post baseline	12 (23.5)	19 (39.6)

FIG. 36



NEO1(NCT01898364): open-label, multicenter, multinational, ascending dose study of avalglucosidase alfa in previously treated and treatment-naïve LOPD participants enrolled in the NEO1 study[5]
Treatment-naïve participants (Naïve Group*)
Avalglucosidase alfa 5,10, or 20 mg/kg qow
Previously treated participants (Switch Group+)
Avalglucosidase alfa 5,10, or 20 mg/kg qow
Open-label treatment
24 weeks
Start August 2013
NEO-EXT (NCT02032524): open label, multicenter, multinational study of avalglucosidase alfa in previously treated and treatment-naïve LOPD participants enrolled in the NEO1 study
Avalglucosidase alfa 5, 10, or 20 mg/kg qow (same dose as NEO1)
All participants switched to 20 mg/kg in 2016
Avalglucosidase alfa 5, 10, or 20 mg/kg qow (same dose as NEO1)
All participants switched to 20 mg/kg in 2016
Open-label treatment
Up to 8 years
Start February 2014
End December 2021

FIG. 37A



Treatment-naïve*, N=10
Previously treated+, N=14
Ava 5 mg/kg qow, n=4
Ava 10 mg/kg qow, n=3
Ava 20 mg/kg qow, n=3
Ava 5 mg/kg qow, n=4
Ava 10 mg/kg qow, n=3
Ava 20 mg/kg qow, n=6
90 days
Screening
Baseline
24 weeks (13 doses)
Open-label treatment
5 weeks
Follow-up

FIG. 37B

	Naïve Group (n=10)	Switch Group (n=14)
Age at NEO1 enrollment, years, mean ± SD (range)	44.8 ± 20.3 (20-78)	46.7 ±14.1 (21-68)
Males, n (%)	3(30)	9(64)
Use of walking device, n (%)	2(20)	3(21)
6MWT distance, m, mean ± SD (median)	449.2 ± 118.36 (488.5)	440.4 ± 141.02 (439.0)
Upright FVC % predicted,* mean ± SD (median)	69.2 ± 19.27 (58.7)	77.3 ±16.45 (75.9)

6MWT, 6-minute walk test; FVC, forced vital capacity; SD, standard deviation
•Calculated according to Quanjer PH, et al. *Eur Respir J.* . 2012;40(6):1324-43

FIG. 37C

			Mean ± SD (range)	
			Naïve Group	Switch Group
Area occupied by glycogen in quadriceps muscle, %			6.0±7.13 (0.6-24.1) (n=10)	65±7.92 (0.6-24.7) (n=14)
MRI	Mercuri grading*	Lower leg	1.3±0.39 (1.0-2.0) (n=8)	1.3±0.37 (1.0-2.0) (n=13)
		Thigh	1.9±0.72 (1.2-2.9) (n=9)	2.3±0.65 (1.2-3.5) (n=13)
	3-point Dixon fat fraction, %	Lower leg	5.7±2.54 (2.0-10.7) (n=9)	7.2±2.10 (4.0-11.0) (n=11)
		Thigh	8.1±3.17 (5.6-14.0) (n=9)	17.3±15.31 (3.0-54.9) (n=11)
	T2 water with B1^{+}, ms	Lower leg	37.2±1.82 (34.1-39.7) (n=10)	39.1±3.28 (34.4-43.8) (n=14)
		Thigh	37.1±1.52 (34.9-39.8) (n=10)	36.7±2.81 (30.4-41.1) (n=14)
	Trophicity index, ms	Thigh	4296±890 (2956-5388) (n=10)	4642±1807 (1702-7596) (n=14)
Motor function	6MWT % predicted		69.6±11.84 (46.7-86.9) (n=10)	67.2±20.43 (29.7-102.2) (n=14)
	GSGC functional ability score		11.0±5.19 (4.0-18.0) (n=10)	11.8±5.98 (4.0-21.0) (n=14)
	GMFM-88 functional strength total (D+E)		82.2±14.46 (59.3-95.6) (n=10)	78.5±17.11 (48.5-95.6) (n=14)
	QMFT total score		47.2±10.84 (31.0-61.0) (n=10)	44.7±12.80 (25.0-64.0) (n=14)
	HHD % predicted lower body		46.9±15.00 (21.3-67.7) (n=10)	43.6±16.86 (14.2-75.5) (n=14)

6MWT,6-minute walk test; GMFM-88, Gross Motor Function Measure-88; GSGC, Gait, Stair, Gowers' Maneuver, Chair; HHD, hand-held dynamometry; QMFT, Quick Motor Function Test; SD, standard deviation

*Mercuri Grading: 1 = normal appearance; 2 = mild involvement; 3 = moderate involvement; 4 = severe involvement

$^{+}$T2 with B1: abnormal value defined as >39 ms

FIG. 38



Naïve Group
Switch Group
≥2 = abnormal
<2 = normal
Mercuri Grade
Quadriceps Biopsy % Glycogen
0
0.5
1
1.5
2
2.5
3
3.5
4
0
5
10
15
20
25
30

FIG. 39




FIG. 40A




FIG. 40B




FIG. 40C




FIG. 40D



FVC, % predicted
-0.13
2.43
4.99
-6 -4 -2 0 2 4 6
6MWT, m
1.33
30.01
58.69
-75 -50 -25 0 25 50 75
6MWT, % predicted
0.25
4.71
9.17
-10 -8 -6 -4 -2 0 2 4 6 8 10
MIP, % predicted
-1.63
4.4
10.44
MEP, % predicted
-5.7
2.51
10.73
-12 -9 -6 -3 0 3 6 9 12
HHD composite score
Lower extremity
-26.56
106.97
240.5
Upper extremity
-44.76
63.87
172.51
-250 -200 -150 -100 -50 0 50 100 150 200 250
QMFT, total score
0.22
2.08
3.95
-5 -4 -3 -2 -1 0 1 2 3 4 5
GMFM-88
Dimension D
-0.02
2.58
5.18
Dimension E
-0.09
2.54
5.18
-6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6
GSGC, total score
-0.37
-1.31
-2.25
3 2 1 0 -1 -2 -3
Favors Alglucosidase Alfa
Favors Avalglucosidase Alfa

FIG. 41A




FIG. 41B

SUBSTITUTE SHEET (RULE 26)




FIG. 42A




FIG. 42B




FIG. 43A




FIG. 43B